Abstract:Abstract Background For communities of people living with hemophilia and other genetic conditions, gene therapy could represent a paradigm shift in treatment strategies. As investigational therapeutic modalities such as gene therapy become more widely used and discussed, there is a critical need for all stakeholders to communicate using a lexicon that is intelligible, accurate, consistent, and representative of novel treatments. In doing so, expectations can be more carefully managed and potential risks, benefits, and limitations better understood. In recognition of this need, a first-ever study of gene therapy lexicon was conducted using established methods of market research and linguistic analysis. Methods Ninety-four participants representing hematologists, nurses, caregivers, and people with hemophilia A, in six countries (US, UK, Spain, Germany, France, Italy) took part in a series of in-depth interviews, face-to-face focus groups, an advisory board meeting, and online group interviews to develop, refine, and test verbal, written, and pictorial language concepts through a three-phase iterative process. Sessions were conducted in local languages using detailed discussion guides. Feedback from participants was captured using real-time instant-response dial testing to measure moment-by-moment emotional responses to language stimuli. Semiquantitative analysis of the responses informed selection of preferred language concepts for final testing, and qualitative discussion explored preference rationale. Participants also completed polling and forced rank and choice written exercises. Results Study feedback showed that the hemophilia community has preferences around consistent lexicon to describe hemophilia and its management. Expert linguistic analysis of feedback from the three phases enabled agreement of a consensus lexicon of vocabulary and an optimized summary narrative for talking about gene therapy amongst people affected by hemophilia A. Preferences were largely consistent across audiences and countries, although some country-specific recommendations were made. A representative summary phrase was agreed: “Gene therapy is being studied in clinical trials with the aim to allow the body to produce factor VIII protein on its own”. Conclusions The use of preferred language across different stakeholders increases understanding and comfort during discussions of novel and complex therapeutic modalities such as gene therapy. Consistent use of community-informed lexicon minimizes miscommunication and facilitates informed decision-making regarding potential future treatment opportunities.

Clinician's perspectives on gene therapy for Alzheimer's disease: A qualitative study

From Lab Bench to Hope: Emerging Gene Therapies in Clinical Trials for Alzheimer's Disease

Advances and Challenges in Gene Therapy for Alzheimer's Disease

Emerging Gene Therapies for Alzheimer's and Parkinson's Diseases: An Overview of Clinical Trials and Promising Candidates

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Nanotechnology-based Gene Therapy As a Credible Tool in the Treatment of Alzheimer’s Disease

A review of the advances, insights, and prospects of gene therapy for Alzheimer's disease: A novel target for therapeutic medicine

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

Bio–Nano Toolbox for Precision Alzheimer's Disease Gene Therapy

Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study

Perspectives of the Friedreich ataxia community on gene therapy clinical trials

Ethics of gene and cell therapy development for neurologic disorders

Somatic Gene Therapy: Ethics and Access

Gene therapy for CNS disorders: modalities, delivery and translational challenges

Gene therapy for neurodegenerative disorders: advances, insights and prospects

A multinational survey of potential participant perspectives on ocular gene therapy

Genetic testing and Alzheimer disease: recommendations of the Stanford Program in Genomics, Ethics, and Society

Gene therapy for ALS: A review

Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement

Benefits and risks of FDA‐approved amyloid‐targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician‐patient engagement

Lived Experience of Patients & Caregivers in Rare Genetic Neurological Gene Therapy Clinical Trials in Children